Vnitr Lek 2008, 54(6):604-608

Late recurrences of atrial fibrillation in patients after direct-current cardioversion

M. Gurčiková*, J. Kalužay, S. Remišová, O. Jurkovičová, P. Ponťuch
IV. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Peter Ponťuch, CSc.

Aim:
To analyze factors after successful direct-current cardioversion in patients with atrial fibrillation and to explore late recurrences of the arrhythmia.

Methods:
Forty-three patients with atrial fibrillation without associated valvular heart disease, who underwent non-emergent cardioversion within the years 2002-2006, were included. We retrospectively analyzed clinical data from the medical records. Late reccurence of the arrhythmia was defined as arrhythmia in patients discharged with sinus rhythm.

Results:
Median follow-up of the patients was 33 (17, 48) months. We found 20 late recurrences of atrial fibrillation in the total group of 43 patients after successful direct-current cardioversion (46.5%). In a 6-month period after direct-current cardioversion the recurrence of arrhythmia was found in two patients, in a one-year period in 6 patients and in a period longer than one year in 12 patients. Median time to recurrence was 15 (6, 33) months. Females relapsed more frequently than males (p < 0.02), what could be explained by higher age, incidence of hypertension and thyreopathy in females. Patients with a history of thyropathy had more frequent occurrence of arrhythmia, despite normal values of TSH, as compared to patients without a history of thyropathy (p < 0.04). Patients with recurrence of the atrial fibrillation had higher systolic pressure (130 vs 120 mm Hg, p < 0.05) and pulse arterial pressure (50 vs 40 mm Hg, p < 0.01) after cardioversion. No significant difference between the two groups in age, left atrium diameter, left ventricle ejection fraction and cardiovascular, or non-cardiovascular risk factors was found.

Conclusion:
Despite successful direct-current cardioversion, the risk of late recurrence of the atrial fibrillation in a following period is at least 46.5%. Females, patients with a history of thyropathy and those with higher systolic and pulse arterial pressures are at higher risk of late recurrences.

Keywords: atrial fibrillation; direct-current cardioversion; late recurrences of atrial fibrillation

Received: February 8, 2008; Accepted: March 15, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gurčiková M, Kalužay J, Remišová S, Jurkovičová O, Ponťuch P. Late recurrences of atrial fibrillation in patients after direct-current cardioversion. Vnitr Lek. 2008;54(6):604-608.
Download citation

References

  1. Friberg J, Buch P, Scharling H et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672. Go to original source... Go to PubMed...
  2. Frick M, Frykman V, Jensen-Urstad M et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24: 238-244. Go to original source... Go to PubMed...
  3. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate. Int J Cardiol 2006; 107: 389-394. Go to original source... Go to PubMed...
  4. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394. Go to original source... Go to PubMed...
  5. Page RL, Tilsch TW, Connolly SJ et al. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003; 107: 1141-1145. Go to original source... Go to PubMed...
  6. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844. Go to original source... Go to PubMed...
  7. Katritsis DG, Toumpoulis IK, Giazitzoglou E et al. Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol 2005; 13: 203-207. Go to original source... Go to PubMed...
  8. Mitchell GF, Vasan RS, Keyes MJ et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007; 297: 709-715. Go to original source... Go to PubMed...
  9. Humphries KH, Kerr CR, Connolly SJ et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-2370. Go to original source... Go to PubMed...
  10. Gurevitz OT, Varadachari CJ, Ammash NM et al. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J 2006; 152: 155. Go to original source... Go to PubMed...
  11. Van Noord T, Tieleman RG, Bosker HA et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004; 6: 343-350. Go to original source... Go to PubMed...
  12. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098. Go to original source... Go to PubMed...
  13. Madrid AH, Peng J, Zamora J et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-1410. Go to original source... Go to PubMed...
  14. Yin Y, Dalal D, Liu Z et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-1846. Go to original source... Go to PubMed...
  15. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719. Go to original source... Go to PubMed...
  16. Hirayama Y, Atarashi H, Kobayashi Y et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005; 69: 671-676. Go to original source... Go to PubMed...
  17. Gammage MD, Parle JV, Holder RL et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007; 167: 928-934. Go to original source... Go to PubMed...
  18. Hrnciar J. Thyrotoxic heart disease. Part II - aspects of treatment of thyrotoxicosis with cardiac involvement. Vnitř Lék 2002; 48: 137-141. Go to PubMed...
  19. Murphy NF, Stewart S, MacIntyre K et al. Seasonal variation in morbidity and mortality related to atrial fibrillation. Int J Cardiol 2004; 97: 283-288. Go to original source... Go to PubMed...
  20. Sojo L, Corcoy R. Seasonal variation in morbidity and mortality related to atrial fibrillation - could thyroid function contribute? Int J Cardiol 2006; 107: 281. Go to original source... Go to PubMed...
  21. Olshansky B, Heller EN, Mitchell LB et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol 2005; 45: 2026-2033. Go to original source... Go to PubMed...
  22. Schotten U, de Haan S, Neuberger HR et al. Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation. Am J Physiol Heart Circ Physiol 2004; 287: H2324-H2331. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.